Home
HelpTest Code HPFH Hemoglobin F Distribution, Blood
Reporting Name
Hb F Distribution, BUseful For
Distinguishing large deletional hereditary persistence of fetal hemoglobin from other conditions with increased percentage of fetal hemoglobin (Hb F)
Determining the distribution of Hb F within red blood cells
Method Name
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood
Flow Cytometry
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole Blood EDTAOrdering Guidance
This test is for hereditary persistence of fetal hemoglobin only. For testing for possible fetal-maternal bleed, see FMB / Fetomaternal Bleed, Flow Cytometry, Blood.
Specimen Required
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Clotted blood | Reject |
Reference Values
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood
Reported as: Heterocellular, Homocellular, or Equivocal
Day(s) Performed
Monday through Friday
CPT Code Information
88184
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HPFH | Hb F Distribution, B | 4579-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 8270 | Hb F Distribution, B | 4579-9 |
| 2104 | Interpretation | 59466-3 |
Clinical Information
More than 75% of the hemoglobin of the newborn is hemoglobin (Hb) F; it diminishes over a period of several months to adult levels, reducing to less than 2% by 1 year of age and less than 1% by 2 years of age.
Hb F may constitute 90% of the total Hb in patients with beta-thalassemia major or other combinations of beta thalassemia and fetal Hb (hereditary persistence of fetal hemoglobin [HPFH]) variants.
Hb F is often mildly to moderately elevated in sickle cell disease, aplastic anemia, acute leukemia, and myeloproliferative disorders such as juvenile myelomonocytic leukemia, hereditary spherocytosis, and alpha-thalassemia minor. It is commonly increased in hemoglobinopathies associated with hemolysis. Hb F increases to as high as 10% during normal pregnancy. Hb F is also increased due to medications such as hydroxyurea, decitabine, and lenalidomide. Elevation in Hb F has a been cited as a discriminator between Diamond-Blackfan congenital pure red cell aplasia (elevated) and transient erythroblastopenia of childhood (normal), but whether this simply reflects the chronicity of anemia inherent to the former condition rather than a specific finding is unclear.
In the common (large deletional) form of the genetic trait HPFH, all of the erythrocytes contain Hb F. When tested by flow cytometry using specificity for Hb F, these HPFH cases display a homocellular distribution pattern of Hb F within the red blood cell population. Other causes of increased Hb F, including delta beta thalassemia, hydroxyurea, and some nondeletional HPFH variants, typically display a heterocellular distribution of Hb F within the erythrocytes, reflecting disparate populations of F cells and cells lacking Hb F. Quantification of Hb F percentage should be determined prior to flow cytometry of Hb F red blood cell distribution to establish the appropriateness of this test. The flow cytometry analysis of elevated Hb F levels is useful when Hb F percentage is 15% to 35% and the clinical differential diagnosis includes large deletional HPFH. Hb F percentages below 15% are likely not due to large deletional HPFH, and the causes of Hb F percentages above 35% are better confirmed by molecular and family studies.
Interpretation
Homocellular distribution of fetal hemoglobin (Hb) is found in large deletional hereditary persistence of fetal Hb.
Heterocellular distribution is found in delta beta thalassemia, medication induced, and other causes of increased Hb F.
An equivocal result indicates the pattern is not typical for either a homocellular or heterocellular distribution.
Cautions
When hemoglobin (Hb) F values are above 35%, most specimens show a homocellular pattern; this does not necessarily indicate hereditary persistence of fetal Hb. Clinical correlation is needed.
Method Description
This assay uses a flow cytometric method with a monoclonal antibody to hemoglobin (Hb) F. Specimens are analyzed by single-color flow cytometry using fluorescein anti-Hb F. In normal adults, a single peak is seen with minimal fluorescence, which corresponds to Hb A. In neonates, a single peak with bright fluorescence is seen, which corresponds to Hb F. In cases of hereditary persistence of fetal Hb (HPFH) only, a single peak is observed, which has a fluorescence intensity intermediate between the normal Hb A and Hb F peaks. This pattern corresponds to the homocellular (pancellular) pattern obtained by the Kleihauer-Betke (K-B) method. In contrast, specimens from infants, transfused neonates, and cases of beta-thalassemia or delta/beta-thalassemia show both Hb A and Hb F peaks, corresponding to the heterocellular pattern of the K-B method. In patients with Hb S/HPFH, a single peak was observed in contrast to patients with homozygous S in which 2 peaks were observed.(Package insert: Invitrogen Fetal Hemoglobin Test Kit with FITC-conjugated Monoclonal Antibody Directed to HbF. Life Technologies Corporation; MAN 0003641, Rev 3.02, 11/21/2019)